Skip to main content
. 2020 Jun 20;43(10):999–1009. doi: 10.1007/s40264-020-00957-w

Table 4.

Top assessed adverse events in the first phase of the study (total number of assessed signals = 293)

Adverse event (MedDRA Preferred Term) Preliminary assessed signals (%)
Headache 19 (6.5)
Pyrexia 11 (3.8)
Drug ineffective 10 (3.4)
Pruritus 10 (3.4)
Urticaria 7 (2.4)
Dizziness 6 (2.0)
Dyspnoea 6 (2.0)
Malaise 6 (2.0)
Nausea 6 (2.0)
Palpitations 6 (2.0)